Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.
Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, Gambell P, Westerman DA, Haurat J, Westwood JA, Scott AM, Kravets L, Dickinson M, Trapani JA, Smyth MJ, Darcy PK, Kershaw MH, Prince HM. Ritchie DS, et al. Among authors: scott am. Mol Ther. 2013 Nov;21(11):2122-9. doi: 10.1038/mt.2013.154. Epub 2013 Jul 8. Mol Ther. 2013. PMID: 23831595 Free PMC article. Clinical Trial.
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.
Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, Smyth FE, Cartwright GA, Power BE, Hönemann D, Prince HM, Darcy PK, Kershaw MH. Westwood JA, et al. Among authors: scott am. Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19051-6. doi: 10.1073/pnas.0504312102. Epub 2005 Dec 19. Proc Natl Acad Sci U S A. 2005. PMID: 16365285 Free PMC article.
Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.
Westwood JA, Murray WK, Trivett M, Shin A, Neeson P, MacGregor DP, Haynes NM, Trapani JA, Mayura-Guru P, Fox S, Peinert S, Honemann D, Prince HM, Ritchie D, Scott AM, Smyth FE, Smyth MJ, Darcy PK, Kershaw MH. Westwood JA, et al. Among authors: scott am. Gene Ther. 2008 Jul;15(14):1056-66. doi: 10.1038/gt.2008.47. Epub 2008 Mar 27. Gene Ther. 2008. PMID: 18369322
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.
Westwood JA, Murray WK, Trivett M, Haynes NM, Solomon B, Mileshkin L, Ball D, Michael M, Burman A, Mayura-Guru P, Trapani JA, Peinert S, Hönemann D, Miles Prince H, Scott AM, Smyth MJ, Darcy PK, Kershaw MH. Westwood JA, et al. Among authors: scott am. J Immunother. 2009 Apr;32(3):292-301. doi: 10.1097/CJI.0b013e31819b7c8e. J Immunother. 2009. PMID: 19242371
TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models.
Meyran D, Zhu JJ, Butler J, Tantalo D, MacDonald S, Nguyen TN, Wang M, Thio N, D'Souza C, Qin VM, Slaney C, Harrison A, Sek K, Petrone P, Thia K, Giuffrida L, Scott AM, Terry RL, Tran B, Desai J, Prince HM, Harrison SJ, Beavis PA, Kershaw MH, Solomon B, Ekert PG, Trapani JA, Darcy PK, Neeson PJ. Meyran D, et al. Among authors: scott am. Sci Transl Med. 2023 Apr 5;15(690):eabk1900. doi: 10.1126/scitranslmed.abk1900. Epub 2023 Apr 5. Sci Transl Med. 2023. PMID: 37018415
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS. Davis ID, et al. Among authors: scott am. Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702. doi: 10.1073/pnas.0403572101. Epub 2004 Jul 13. Proc Natl Acad Sci U S A. 2004. PMID: 15252201 Free PMC article. Clinical Trial.
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.
Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, Poon AM, Hopkins W, Smyth FE, Murone C, MacGregor D, Papenfuss AT, Chappell B, Saunder TH, Brechbiel MW, Davis ID, Murphy R, Chong G, Hoffman EW, Old LJ. Scott AM, et al. Clin Cancer Res. 2007 Jun 1;13(11):3286-92. doi: 10.1158/1078-0432.CCR-07-0284. Clin Cancer Res. 2007. PMID: 17545534 Clinical Trial.
Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.
Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, Brechbiel MW, Murone C, Scott AM. Herbertson RA, et al. Among authors: scott am. Clin Cancer Res. 2009 Nov 1;15(21):6709-15. doi: 10.1158/1078-0432.CCR-09-0536. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825951 Free PMC article. Clinical Trial.
716 results